@article {8124,
	title = {Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer},
	journal = {Annals of Oncology},
	volume = {11},
	year = {2000},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {2000},
	pages = {607 - 612},
	abstract = {Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide i.v. at 2.25 g/m2 (days 1, 2) and etoposide per os at 100 mg daily (days 1- 10) every four weeks. To be eligible for the study patients had to be resistant to platinum and paclitaxel pretreated. Results: Forty-one patients entered the study. The median interval from the previous chemotherapy was 3.9 months. The median number of previous chemotherapeutic regimens was 2. Severe toxicities included neutropenia (41\% of patients), leukopenia (29\%) and thrombocytopenia (13\%). Thirty-five patients are assessable for response. Nine patients responded (22\% of the eligible, 26\% of the assessable), four of them demonstrated complete response to chemotherapy (10\% and 12\%, respectively), while three patients demonstrated stabilization of their progressive disease. After a median follow-up of 18 months, time to progression is 3 months (range 0.9-14.4), duration of response is 9 months (2.5-11) and median survival is 13 months (2.5-37.4+). Conclusions: The combination of ifosfamide with oral etoposide appears to have significant but manageable toxicity and encouraging efficacy in platinum resistant ovarian cancer.},
	keywords = {Chemotherapy, Combination, Etoposide, Ifosfamide, Ovarian cancer},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033948009\&doi=10.1023\%2fA\%3a1008327412571\&partnerID=40\&md5=c620a44957842281f30bd13c1702c5fb},
	author = {Aravantinos, G. and Dimopoulos, M.A. and Kosmidis, P. and Bafaloukos, D. and Papadimitriou, C. and Kiamouris, C. and N. Pavlidis and Sikiotis, K. and Papakostas, P. and Skarlos, D.V.}
}
